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Abstract 
One of the main components of managing a patient with hypertension is deciding which drug to prescribe 
for first-line therapy. This decision should be made primarily on the basis of the best available evidence 
of the drug’s ability to prevent adverse health outcomes of the diseases. The objective of this review is to 
determine the relative effects of different antihypertensive drugs in reducing the incidence of 
cardiovascular outcomes. Articles included in this review were randomized controlled trials and meta-
analysis of RCTs. Relevant articles were obtained from Google scholar database, manual Google search 
and reference lists of retrieved article. Titles and abstracts were assessed for relevance and those 
potentially fulfilling the inclusion criteria were then assessed in full text. The following main outcomes 
were selected: Stroke, myocardial infarction, Coronary heart disease, heart failure, cardiovascular 
mortality and cardiovascular morbidity. The evidence in this review shows the newer antihypertensive 
drugs (CCBs and ACEIs) are better than conventional antihypertensive drugs in preventing stroke. The 
risk of myocardial infarction can be better reduced by using newer antihypertensive drugs like ARBs and 
ACEIs. All of the antihypertensive drugs did not have a significant difference in prevention of 
cardiovascular mortality. In hypertensive patients who had also diabetics the newer drugs have equal 
effectiveness with the conventional once to reduce cardiovascular mortality. The risk of myocardial 
infarction in this type of patients is better reduced by using ACEIs than conventional antihypertensive 
drugs and CCBs. CCBs are better than ACEIs to reduce the risk of stroke. ARB drugs are better for 
diabetic hypertensive patients to prevent cardiovascular mortality and morbidity.  
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1. Introduction 
Hypertension is defined as a systolic blood pressure at or above 140 mmHg and/or a diastolic 
blood pressure at or above 90 mmHg. There are at least 970 million people worldwide who 
have elevated blood pressure (hypertension). In the developed world, about 330 million people 
have hypertension, as do around 640 million in the developing world. The World Health 
Organization rates hypertension as one of the most important causes of premature death 
worldwide and the problem is growing. In 2025 it is estimated there will be 1.56 billion adults 
living with high blood pressure [1]. 
Hypertension is the most important risk factor for premature cardiovascular disease, being 
more common than cigarette smoking, dyslipidemia, and diabetes, which are the other major 
risk factors. Hypertension increases the risk for a variety of cardiovascular diseases, including 
stroke, coronary artery disease, heart failure, and peripheral vascular disease. It accounts for an 
estimated 54 percent of all strokes and 47 percent of all ischemic heart disease events globally 
[1]. The overall goal of treating hypertension is to reduce hypertension associated morbidity 
and mortality. This morbidity and mortality is related to hypertension associated target-organ 
damage (e.g., CV events, cerebrovascular events, heart failure, and kidney disease). Reducing 
CV risk remains the primary purpose of hypertension therapy and the specific choice of drug 
therapy is significantly influenced by evidence demonstrating such CV risk reduction [2]. 
The last few years have seen an enormous number of randomised clinical trials and Meta 
analyses which have served to increase our knowledge and understanding of hypertension. 
One of the main components of managing a patient with hypertension is deciding which drug 
to prescribe for first-line therapy. This decision should be made primarily on the basis of the 
best available evidence of effectiveness that is the drug’s ability to prevent adverse health 
outcomes that are important to the patient. Reliable information about the size of benefits 
achieved with different blood pressure lowering regimens is of great importance. If one 
regimen proved even slightly better than another, then preferential use of the more effective 
regimen might prevent tens of thousands of major cardiovascular events every year.
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This review was undertaken to address the highlight of what 
has been done on the comparative effectiveness of different 
antihypertensive drugs to prevent cardiovascular outcomes. 
For this purpose randomized, controlled trials and Meta 
analytic studies of randomized trials comparing one or more 
drugs against each other or a placebo were selected. Since the 
focus was on cardiovascular event prevention ability of 
antihypertensive drugs, studies which compare anti-
hypertensive drugs interms of fatal and non-fatal 
cardiovascular events like myocardial infarction, stroke, atrial 
fibrillation, congestive heart failure, coronary heart disease 
(CHD), sudden cardiac death, coronary artery disease, 
cardiovascular morbidity and mortality were included in the 
review. 
 
2. Methods 
Articles included in this review were randomized controlled 
trials (RCTs) and meta-analysis of RCTs. Relevant articles 
were obtained from Google scholar database, manual Google 
search and reference lists of retrieved articles. Titles and 
abstracts were assessed for relevance and those potentially 
fulfilling the inclusion criteria were then assessed in full text. 
The following main outcomes were selected: Stroke, 
myocardial infarction, Coronary heart disease, heart failure, 
cardiovascular mortality and cardiovascular morbidity. Non 
RCT studies, non English language studies, studies that have 
not address at least one of the main cardiovascular outcomes 
and abstract only articles were excluded. 
 
3. Result  
3.1 Comparison of cardiovascular outcomes between 
different antihypertensive drugs in non-diabetic 
hypertensive patients 
3.1.1 Conventional anti-hypertensive drugs (diuretics and 
beta blockers) versus newer antihypertensive drugs 
(ACEIs, ARBs and CCBs) 
In the study conducted to evaluate cardiovascular mortality 
and morbidity in elderly hypertensive patients by comparing 
treatment with conventional drugs (diuretics, beta‐blockers) 
with that of newer ones [angiotensin‐converting enzyme 
(ACE) inhibitors, calcium antagonists], the newer therapy 
(ACEI/CCB) was significantly better than “conventional” 
therapy (diuretics/beta‐blockers) in preventing all stroke in 
elderly patients with isolated systolic hypertension. New cases 
of atrial fibrillation were significantly increased by 43% (95% 
CI 1.02–1.99; p = 0.037) on “newer” drugs compared with 
“conventional” therapy, mainly attributable to the calcium 
antagonists. But there were no significant differences between 
the treatment groups with respect to the risks of myocardial 
infarction, sudden death or congestive heart failure. There is 
also no difference between the treatment groups regarding 
prevention of cardiovascular mortality [3]. 
In another study conducted in Sweden on old patients with 
hypertension to compare the effects of conventional and newer 
antihypertensive drugs on cardiovascular mortality and 
morbidity it is found that old and new antihypertensive drugs 
were similar in prevention of cardiovascular mortality or major 
events. According to the study the primary combined end point 
of fatal stroke, fatal myocardial infarction, and other fatal 
cardiovascular disease occurred in 221 of 2213 patients in the 
conventional drugs group (19.8 events per 1000 patient-years) 
and in 438 of 4401 in the newer drugs group (19.8 per 1000; 
relative risk 0.99 [95% CI 0.84-1.16], p=0.89). The combined 
endpoint of fatal and non-fatal stroke, fatal and non-fatal 
myocardial infarction, and other cardiovascular mortality 
occurred in 460 patients taking conventional drugs and in 887 
taking newer drugs (0.96 [0.86-1.08], p=0.49) [4]. 
Prospectively-designed overviews with data from 29 
randomised trials (n=162341) was done to estimate effects of 
strategies based on different drug classes (angiotensin-
converting-enzyme [ACE] inhibitors, calcium antagonists, 
angiotensin-receptor blockers [ARBs], and diuretics or B _ 
blockers) or those targeting different blood pressure goals, on 
the risks of major cardiovascular events and death. According 
to this study In placebo-controlled trials the relative risks of 
total major cardiovascular events were reduced by regimens 
based on ACE inhibitors (22%; 95% CI 17–27) or calcium 
antagonists (18%; 5–29). Greater risk reductions were 
produced by regimens that targeted lower blood pressure goals 
(15%; 5–24). ARB-based regimens reduced the risks of total 
major cardiovascular events (10%; 4–17) compared with 
control regimens. There were no significant differences in total 
major cardiovascular events between regimens based on ACE 
inhibitors, calcium antagonists, or diuretics or B blockers, 
although ACE-inhibitor-based regimens reduced blood 
pressure less. There was evidence of some differences between 
active regimens in their effects on cause-specific outcomes. 
For every outcome other than heart failure, the difference 
between randomised groups in achieved blood pressure 
reduction was directly related to the observed difference in 
risk. Treatment with any commonly-used regimen reduces the 
risk of total major cardiovascular events, and larger reductions 
in blood pressure produce larger reductions in risk [5]. 
 
3.1.2 Diuretics versus other drugs 
A meta analytic study done by taking 23 trials showed in the 
trials that had an untreated control group, low-dose thiazide 
therapy was associated with a significant reduction in the risk 
of death (RR 0.89, 95% CI 0.81–0.99), stroke (RR 0.66, 95% 
CI 0.56–0.79), coronary artery disease (RR 0.71, 95% CI 
0.60–0.84) and cardiovascular events (RR 0.68, 95% CI 0.62–
0.75). High-dose thiazide therapy, b-blocker therapy and 
calcium channel blocker therapy did not significantly reduce 
the risk of death or coronary artery disease. In both the drug–
drug and the drug–no treatment comparison trials, thiazides 
were significantly better at reducing systolic blood pressure 
than the other drug classes [6]. 
In a randomized, double-blind, active-controlled clinical trial 
conducted to determine Major Outcomes in High-Risk 
Hypertensive Patients Randomized to Angiotensin-Converting 
Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic, 
thiazide-type diuretics are superior in preventing 1 or more 
major forms of CVD so they should be preferred for first-step 
antihypertensive therapy [7]. 
In a prospective, randomised, double-blind trial in Europe and 
Israel in 6321 patients aged 55–80 years with hypertension 
Primary outcomes occurred in 200 (6·3%) patients in the 
nifedipine (CCB) group and in 182 (5·8%) in the co-amilozide 
(diuretic combination) group (18·2 vs 16·5 events per 1000 
patient-years; relative risk 1·10 [95% CI 0·91–1·34], p=0·35). 
This shows Nifedipine once daily and co-amilozide were 
equally effective in preventing overall cardiovascular or 
cerebrovascular complications. The choice of drug can be 
decided by tolerability and blood-pressure response rather than 
long-term safety or efficacy [8]. 
Another study that compared the outcomes in older subjects 
with hypertension who were treated with angiotensin-
converting– enzyme (ACE) inhibitors with the outcomes in 
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those treated with diuretic agents, the rates of nonfatal 
cardiovascular events and myocardial infarctions decreased 
with ACE-inhibitor treatment, whereas a similar number of 
strokes occurred in each group (although there were more fatal 
strokes in the ACE-inhibitor group). So Initiation of 
antihypertensive treatment involving ACE inhibitors in older 
subjects, particularly men, appears to lead to better outcomes 
than treatment with diuretic agents, despite similar reductions 
of blood pressure [9]. 
 
3.1.3 Conventional anti-hypertensive drugs (Diuretics and 
beta blockers) versus ARBs 
A single blind, randomized, prospective study conducted in 
1999–2002 and employing a total of 2,048 essential 
hypertensive subjects aged 35–79 years in Japan shows, 
conventional treatment was superior to candesartan (ARB)-
based treatment in reducing the incidence of stroke in the 
patients without a past history of cardiovascular diseases (66% 
reduction; RR: 0.34; CI: 0.16–0.69; p<0.05). However ARB-
based antihypertensive treatment was superior to the 
conventional treatment for reducing the risk of stroke and 
myocardial infarction, especially in the patients with a past 
history of cardiovascular diseases. According to this research 
there was a 39% reduction in hospitalization for stroke (5.8 vs. 
9.4 cases: relative risk [RR]: 0.61; 95% confidence interval 
[CI]: 0.41–0.84; p<0.05) and a 57% reduction in 
hospitalization for myocardial infarction (RR: 0.44; CI: 0.21–
0.84; p<0.05) with the candesartan-based treatment compared 
with the conventional treatment. In spite of this there was no 
significant reduction in the incidence of congestive heart 
failure (15% reduction: 4.3vs. 5.0; RR: 0.85; CI: 0.57–1.26) 
[10]. 
 
3.1.4 Conventional anti-hypertensive drugs (Diuretics and 
beta blockers) versus ACEIs or CCBs 
A meta-analysis study done by extracting summary statistics 
regarding CHD and stroke from 28 outcome trials that 
compared either ACEIs or CCBs with diuretics, β-blockers, or 
placebo for a total of 179 122 patients, shows there were no 
significant differences in CHD risk between regimens based 
on diuretics/β-blockers and regimens based on ACEIs 
(P=0.46) or CCBs (P=0.52). The risk of stroke was reduced by 
CCBs (P=0.041) but not by ACEIs (P=0.15) compared with 
diuretics/β-blockers. Prevention of CHD was explained by 
systolic BP reduction (P<0.001) and use of ACEIs (P=0.028), 
whereas prevention of stroke was explained by systolic BP 
reduction (P=0.001) and use of CCBs (P=0.042). These 
findings confirm that BP lowering is fundamental for 
prevention of CHD and stroke. However, over and beyond BP 
reduction, ACEIs appear superior to CCBs for prevention of 
CHD, whereas CCBs appear superior to ACEIs for prevention 
of stroke [11]. 
A randomised intervention trial conducted in Sweden and 
Finland to compare the effects of ACE inhibition and 
conventional therapy on cardiovascular morbidity and 
mortality in patients with hypertension ACE inhibitor 
(Captopril) and conventional treatment did not differ in 
efficacy in preventing cardiovascular morbidity and mortality 
[12]. 
 
3.1.5 Comparative effectiveness of the newer 
antihypertensive drugs (ARBs, CCBs, ACEIs)  
A study designed to compare the long-term effects of the 
angiotensin II receptor blocker (candesartan) and the calcium 
channel blocker (amlodipine) on the incidence of 
cardiovascular events, represented as a composite of sudden 
death and cerebrovascular, cardiac, renal, and vascular events 
in high-risk Japanese hypertensive patients shows the 2 
treatment-based regimens produced no significant differences 
in cardiovascular morbidity or mortality in the high-risk 
Japanese hypertensive patients (hazard ratio: 1.01; 95% CI: 
0.79 to 1.28; P_0.969). In each primary end point category, 
there was no significant difference between the 2 treatment-
based regimens. New-onset diabetes occurred in fewer patients 
taking candesartan (8.7/1000 person-years) than in those 
taking amlodipine (13.6/1000 person-years), which resulted in 
a 36% relative risk reduction (hazard ratio: 0.64; 95% CI: 0.43 
to 0.97; P_0.033) [13]. 
The Valsartan Antihypertensive Long-term Use Evaluation 
(VALUE) trial was designed to test the hypothesis that for the 
same blood-pressure control, valsartan would reduce cardiac 
morbidity and mortality more than amlodipine in hypertensive 
patients at high cardiovascular risk. According to this study 
Blood pressure was reduced by both treatments, but the effects 
of the amlodipine-based regimen were more pronounced, 
especially in the early period (blood pressure 4·0/2·1 mm Hg 
lower in amlodipine than valsartan group after 1 month; 
1·5/1·3 mm Hg after 1 year; p<0·001 between groups). The 
primary composite endpoint occurred in 810 patients in the 
valsartan group (10·6%, 25·5 per 1000 patient-years) and 789 
in the amlodipine group (10·4%, 24·7 per 1000 patient-years; 
hazard ratio 1·04, 95% CI 0·94—1·15, p=0·49). Therefore the 
main outcome of cardiac disease did not differ between the 
treatment groups [14]. 
A meta-analysis performed by taking 20 cardiovascular 
morbidity–mortality trials to analyse the effects of RAAS 
inhibitors as a class of drugs, as well as of angiotensin-
converting enzyme (ACE) inhibitors and AT1 receptor 
blockers (ARBs) separately, on all-cause mortality shows 
RAAS inhibition was associated with a 5% reduction in all-
cause mortality (HR: 0.95, 95% CI: 0.91–1.00, P ¼ 0.032), 
and a 7% reduction in cardiovascular mortality (HR: 0.93, 
95% CI: 0.88–0.99, P ¼ 0.018). The observed treatment effect 
resulted entirely from the class of ACE inhibitors, which were 
associated with a significant 10% reduction in all-cause 
mortality (HR: 0.90, 95% CI: 0.84–0.97, P ¼ 0.004), whereas 
no mortality reduction could be demonstrated with ARB 
treatment (HR: 0.99, 95% CI: 0.94–1.04, P ¼ 0.683). This 
difference in treatment effect between ACE inhibitors and 
ARBs on all-cause mortality was statistically significant (P-
value for heterogeneity 0.036) (15). 
The overview of placebo-controlled trials of ACE inhibitors (4 
trials, 12124 patients mostly with coronary heart disease) 
revealed reductions in stroke (30% [95% CI 15–43]), coronary 
heart disease (20% [11–28]), and major cardiovascular events 
(21% [14–27]). The overview of placebo-controlled trials of 
calcium antagonists (two trials, 5520 patients mostly with 
hypertension) showed reductions in stroke (39% [15–56]) and 
major cardiovascular events (28% [13–41]). In the overview of 
trials comparing blood pressure- lowering strategies of 
different intensity (three trials, 20408 patients with 
hypertension), there were reduced risks of stroke (20% [2–
35]), coronary heart disease (19% [2–33]), and major 
cardiovascular events (15% [4–24]) with more intensive 
therapy. In the overviews comparing different antihypertensive 
regimens (eight trials, 37872 patients with hypertension), 
several differences in cause-specific effects were seen between 
calcium antagonist- based therapy and other regimens, but 
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each was of borderline significance. Strong evidence of 
benefits of ACE inhibitors and calcium antagonists is provided 
by the overviews of placebo-controlled trials. There is weaker 
evidence of differences between treatment regimens of 
differing intensities and of differences between treatment 
regimens based on different drug classes [16]. 
 
3.2 Comparisons of cardiovascular outcomes between 
different antihypertensive drugs in hypertensive patients 
who have diabetics 
The benefits of treating hypertension in elderly diabetic 
patients, in terms of achieving reductions in cardiovascular 
morbidity and mortality, have been documented in several 
recent prospective trials. There has, however, been some 
controversy regarding the effect of different antihypertensive 
drugs on the frequency of cardiovascular events in this group 
of patients. 
 
3.2.1 Conventional anti-hypertensive drugs (Diuretics and 
beta blockers) versus newer antihypertensive drugs 
(ACEIs, ARBs and CCBs) 
In one of a prospective, randomized, open trial with blinded 
endpoint evaluation treatment of hypertensive diabetic patients 
with conventional antihypertensive drugs (diuretics, β-
blockers, or both) seemed to be as effective as treatment with 
newer drugs such as calcium antagonists or ACE inhibitors. In 
this study 6614 elderly patients aged 70-84 years; 719 of them 
had diabetes mellitus at the start of the study (mean age 75.8 
years) were randomly assigned to one of three treatment 
strategies: conventional antihypertensive drugs (diuretics or β-
blockers), calcium antagonists, or angiotensin converting 
enzyme (ACE) inhibitors. Reduction in blood pressure was 
similar in the three treatment groups of diabetics. The 
prevention of cardiovascular mortality was also similar; the 
frequency of this primary endpoint did not differ significantly 
between the three groups. There were, however, significantly 
fewer (P = 0.025) myocardial infarctions during ACE inhibitor 
treatment (n = 17) than during calcium antagonist treatment 
(n = 32; relative risk 0.51, 95% confidence interval 0.28-0.92); 
but a (non-significant) tendency to more strokes during ACE 
inhibitor treatment (n= 34 compared with n = 29; relative risk 
1.16, 95% confidence interval 0.71-1.91) [17]. 
In another study done in diabetic patients to compare the 
effects of losartan and atenolol on cardiovascular morbidity 
and mortality, Losartan was found to be more effective than 
atenolol in reducing cardiovascular morbidity and mortality as 
well as mortality from all causes. This shows Losartan seems 
to have benefits beyond blood pressure reduction than 
atenolol [18]. 
The Captopril Prevention Project (CAPPP) evaluated the 
effects of an ACE inhibitor–based therapeutic regimen on 
cardiovascular mortality and morbidity in hypertension. The 
study takes 572 hypertensive patients who had diabetes at 
baseline and were studied according to a prospective, 
randomized, open, blinded end point trial design. The patients 
were randomized to receive either captopril or conventional 
antihypertensive treatment (diuretics and/or β-blockers). The 
primary end point, fatal and nonfatal myocardial infarction and 
stroke as well as other cardiovascular deaths, was markedly 
lower in the captopril than in the conventional therapy group 
(relative risk [RR] = 0.59; P = 0.018). Specifically, 
cardiovascular mortality, defined as fatal stroke and 
myocardial infarction, sudden death, and other cardiovascular 
death, tended to be lower in the captopril group (RR = 
0.48; P = 0.084), and no difference was observed between the 
study groups for stroke (RR = 1.02; P = 0.96). Myocardial 
infarctions were less frequent in the captopril group than in the 
conventional therapy group (RR = 0.34; P = 0.002). 
Furthermore, total mortality was lower in the captopril as 
compared with the conventional therapy group (RR = 
0.54; P = 0.034). Patients with impaired metabolic control 
seemed to benefit the most from ACE inhibitor–based therapy 
[19]. 
 
3.2.2 Comparative effectiveness of the newer 
antihypertensive drugs (ARBs, CCBs, ACEIs) 
Study of Comparison Between Valsartan and Amlodipine 
Regarding Cardiovascular Morbidity and Mortality in 
Hypertensive Patients With Glucose Intolerance shows 
Patients in the valsartan group had a significantly lower 
incidence of heart failure than in the amlodipine group (hazard 
ratio: 0.20 [95% CI: 0.06–0.69]; P_0.01). Other components 
and all-cause mortality were not significantly different 
between the 2 groups. Composite cardiovascular outcomes 
were comparable between the valsartan- and amlodipine based 
treatments in Japanese hypertensive patients with glucose 
intolerance. Admission because of heart failure was 
significantly less in the valsartan group [20]. 
Study on the incidence of cardiovascular complications in 
patients with non-insulin-dependent diabetes mellitus and 
hypertension who were randomly assigned to treatment with 
either the calcium-channel blocker (nisoldipine) or the 
angiotensin-converting– enzyme inhibitor (enalapril) shows 
nisoldipine was associated with a higher incidence of fatal and 
nonfatal myocardial infarctions (a total of 25) than enalapril 
(total, 5) (risk ratio 9.5; 95 percent confidence interval, 2.3 to 
21.4) [21]. 
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Table 1: Comparison of the effect of antihypertensive drugs on cardiovascular outcomes 
 
 
Comparison of 
Antihypertensive drugs in non-diabetic patients 
Cardiovascular outcome comparision reference 
Preventing Stroke 
New > conventional 3* 
conventional > ARB (candesartan) 8# 
ARB (candesartan) >conventional 8” 
CCB > conventional 9 
ACEI < CCB 16 
atrial fibrillation incidence New(CCB)> conventional 3* 
Reduction in the risk of myocardial infarction 
New =conventional 3* 
ARB (candesartan) >conventional 8” 
ACEI > diuretics 10 
Diuretics >BB 16 
Prevention of heart failure 
New =conventional 3* 
ACEI > CCB 16 
Diuretics > CCB/BB/α Blocker 16 
prevention of cardiovascular mortality 
 
New =conventional 3* 
New =conventional 4 
ACE(captopril)=conventional 5 
ACEI (Candesartan) =CCB (amlodipine) 12 
Valsartan(ARB) = amlodipine(CCB) 13 
prevention of cardiovascular morbidity 
ACE(captopril)=conventional 5 
Diuretics(tiazide)>ACEI/CCB 7 
ACEI > diuretics 10 π 
ACEI (Candesartan) =CCB (amlodipine) 12 
Valsartan(ARB) = amlodipine(CCB) 13 
Reduction of CHD risk New ( ACEI/CCB) =conventional 9 
Comparison of Antihypertensive drugs in diabetic patients 
Reduction in the risk of myocardial infarctions 
ACEI > CCB 17 
ACEI (captopril) > conventional 19
ACEI (enalapril) >CCB(nisoldipine) 21 
Reduction in the risk Stroke ACEI < CCB 17 ACEI (captopril) = conventional 19 
prevention of cardiovascular mortality Losartan (ARB) > atenolol (BB) 18 New ( ACEI/CCB) =conventional 17 
prevention of cardiovascular morbidity Losartan (ARB) > atenolol (BB) 18 
Prevention of heart failure Valsartan (ARB) >amlodipine(CCB) 20^
*- For elderly patients with isolated systolic hypertension 
# -essential hypertensive patients without a past history of cardiovascular diseases 
“-essential hypertensive patients with a past history of cardiovascular diseases 
^ -hypertensive patients with glucose intolerance.  
 Π -Male hypertensive patients 
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Table 2: Summary of descriptive review of articles 
 
Topic Purpose Design & sample 
Outcomes and 
Intervention Results 
Conclusions & 
Implications 
Major Outcomes in High-
Risk Hypertensive Patients 
Randomized to 
Angiotensin-Converting 
Enzyme Inhibitor or Calcium 
Channel Blocker 
vs Diuretic: 2002 
To determine whether treatment 
with a calcium channel blocker 
or an angiotensin converting 
enzyme inhibitor lowers the 
incidence of coronary heart 
disease (CHD) or other 
cardiovascular disease (CVD) 
events vs treatment with a 
diuretic 
-A randomized, double-blind, 
active-controlled clinical 
trial. 
-A total of 33,357 
participants aged 55 years or 
older with 
hypertension and at least 1 
other CHD risk factor from 
623 North American centers 
-chlorthalidone, 12.5 to 25 mg/d (n = 15 255); 
amlodipine, 2.5 to 10 mg/d (n = 9048); or 
lisinopril, 10 to 40 mg/d (n = 9054) for 
planned follow-up of approximately 4 to 8 
years. 
-The primary outcome was combined fatal 
CHD or nonfatal myocardial infarction, 
analyzed by intent-to-treat. 
-Secondary outcomes were mortality, stroke, 
combined CHD 
and combined CVD 
 
-Compared with chlorthalidone, the 
relative risks were 0.98 for amlodipine and 0.99 
for lisinopril -mortality did not differ between 
groups 
-For amlodipine vs chlorthalidone, secondary 
outcomes were similar except 
for a higher 6-year rate of HF with amlodipine 
(10.2% vs 7.7%; RR, 1.38. 
-lisinopril had higher 6-year rates of combined 
CVD (33.3% vs 
30.9%; RR, 1.10; stroke (6.3% vs 5.6%; RR, 
1.15; and 
HF (8.7% vs 7.7%; RR, 1.19; 
Thiazide-type diuretics are 
superior in preventing 1 or more 
major forms of CVD 
 
Morbidity and mortality in 
patients randomised to 
double-blind 
treatment with a long-acting 
calcium-channel blocker or 
diuretic 2000 
 
To compare the effects of the 
calcium-channel blocker, 
nifedipine once daily with the 
diuretic combination 
coamilozide 
on cardiovascular mortality and 
morbidity in high risk 
patients with hypertension. 
a prospective, randomised, 
double-blind trial 
in Europe and Israel in 6321 
patients aged 55–80 years 
with hypertension 
Patients are at risk to develop 
cardiovascular disease 
nifedipine 30 mg in a long-acting 
formulation (n=3157), or co-amilozide 
(hydrochlorothiazide 25g plus amiloride 2·5 
mg; n=3164). 
-The primary outcome was cardiovascular 
death, myocardial infarction, heart failure, or 
stroke. 
Primary outcomes occurred in 200 (6·3%) 
patients in 
the nifedipine group and in 182 (5·8%) in the 
co-amilozide 
group (18·2 vs 16·5 events per 1000 patient-
years; relative 
risk 1·10 [95% CI 0·91–1·34], p=0·35). 
Nifedipine once daily and co-
amilozide were 
equally effective in preventing 
overall cardiovascular or 
cerebrovascular complications. 
 
 
Effects of Candesartan 
Compared With Amlodipine 
in 
Hypertensive Patients With 
High Cardiovascular Risks 
2008 
to compare the long-term 
effects of the angiotensin II 
receptor blocker, candesartan 
and the calcium channel blocker, 
amlodipine on the incidence 
of cardiovascular events, 
in high-risk Japanese 
hypertensive patients. 
prospective, randomized, 
open-label study with 
blinded assessment of the 
end point in 4728 Japanese 
hypertensive patients (mean 
age: 63.8 years; mean body 
mass 
index: 24.6 kg/m2). Patients 
were followed for an average 
of 3.2 years. 
-Primary end points (composite of the 
following events) Sudden death: unexpected 
death that happened within 24 hours without 
external causes Cerebrovascular events: stroke 
or transient ischemic attack Cardiac events: 
heart failure, angina pectoris, or acute 
myocardial infarction Renal events: serum 
creatinine concentration _4.0 mg/dL, doubling 
of 
the serum creatinine concentration (however, 
creatinine _2.0 mg/dL is not regarded as an 
event), or end-stage renal disease Vascular 
events: dissecting aortic aneurysm or 
arteriosclerotic occlusion of a peripheral 
artery 
-Secondary and prespecified end points 
All-cause deaths, New-onset diabetes 
Discontinuance of treatment because of 
adverse events 
Intervention 
Candesartan cilexetil (4 to 8 mg/d. When the 
patient’s blood pressure (BP) did 
not reach the targets for controlled BP, the 
dose was increased to 12 mg/d. ) or 
amlodipine besylate (2.5 to 5.0 mg/d and was 
increased to 10.0 mg/d when necessary). 
Primary cardiovascular events occurred 
in 134 patients with both the candesartan- and 
amlodipine-based regimens. The 2 treatment-
based regimens produced 
no significant differences in cardiovascular 
morbidity or mortality in the high-risk Japanese 
hypertensive patients 
(hazard ratio: 1.01; 95% CI: 0.79 to 1.28; 
P_0.969). In each primary end point category, 
there was no significant 
difference between the 2 treatment-based 
regimens. New-onset diabetes occurred in fewer 
patients taking candesartan 
(8.7/1000 person-years) than in those taking 
amlodipine (13.6/1000 person-years), which 
resulted in a 36% relative risk reduction (hazard 
ratio: 0.64; 95% CI: 0.43 to 0.97; P_0.033). 
candesartan-based and 
amlodipinebased regimens 
produced no statistical differences 
in terms of the primary 
cardiovascular end point, whereas 
candesartan prevented new-onset 
diabetes more effectively than 
amlodipine. 
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A Comparison of Outcomes 
with Angiotensin-
Converting–Enzyme 
Inhibitors and Diuretics for 
Hypertension in the Elderly 
2003 
To test the hypothesis that agents 
which inhibit the renin–
angiotensin system confer 
benefit beyond the reduction of 
blood pressure alone. 
a prospective, randomized, 
open-label study with 
blinded assessment of end 
points in 6083 subjects (95 
percent of whom were white) 
with hypertension who were 
65 to 84 years of age and 
received 
health care at 1594 family 
practices. Subjects were 
followed for a median of 4.1 
years 
coronary events, including 
myocardial infarction, sudden or rapid death 
from 
cardiac causes, other deaths from coronary 
causes, 
or coronary events associated with therapeutic 
procedures involving the coronary arteries; 
other cardiovascular events, including heart 
failure, acute occlusion of a major feeding 
artery in any vascular bed other than cerebral 
or coronary, death from noncoronary cardiac 
causes, dissecting or ruptured aortic 
aneurysm, or death from vascular causes; and 
cerebrovascular events, including stroke and 
transient ischemic attacks. 
3044 subjects were assigned to the ACE-
inhibitor 
3039 subjects were assigned to the diuretic 
group. Subjects were recruited over 
a 3-year period and were followed for a 
median of 
4.1 years, for a total of 24,702 patient-years of 
observation. 
There were 695 cardiovascular events or deaths 
from any cause in the ACE-inhibitor group (56.1 
per 1000 patient-years) and 736 cardiovascular 
events or deaths from any cause in the diuretic 
group (59.8 per 1000 patient years; 
the hazard ratio for a cardiovascular event or 
death with ACE-inhibitor treatment was 0.89 
[95 percent confidence interval, 0.79 to 1.00]; 
P=0.05). 
The rates of nonfatal cardiovascular events and 
myocardial infarctions decreased with ACE-
inhibitor treatment, whereas a similar number of 
strokes occurred in each group (although there 
were more fatal strokes in the ACE-inhibitor 
group). 
Initiation of antihypertensive 
treatment involving ACE 
inhibitors in older subjects, 
particularly 
men, appears to lead to better 
outcomes than treatment with 
diuretic agents, despite similar 
reductions of blood pressure 
Effect of angiotensin-
converting-enzyme inhibition 
compared with 
conventional therapy on 
cardiovascular morbidity and 
mortality in hypertension. 
(1999) 
to compare the effects of ACE 
inhibition and conventional 
therapy on cardiovascular 
morbidity and 
mortality in patients with 
hypertension. 
-prospective, randomised, 
open trial with blinded 
endpoint evaluation. 
10985 patients were 
enrolled at 536 health centres 
in Sweden and Finland. 
-Patients aged 25–66 years 
with a measured diastolic 
blood pressure of 100 mm 
Hg or more 
The primary endpoint was a composite of fatal 
and non-fatal myocardial infarction, stroke, 
and other cardiovascular deaths. 
intervention 
captopril or conventional antihypertensive 
treatment (diuretics, b-blockers, or both). The 
initial dose of captopril was 50 mg daily given 
in one or two doses. In the group receiving 
conventional treatment, atenolol and 
metoprolol were the most 
commonly used b-blockers, and 
hydrochlorothiazide and bendrofluazide the 
most common diuretics. The initial dose of 
atenolol and metoprolol was 50–100 mg once 
daily. Hydrochlorothiazide was given as 25 
mg once daily, and bendrofluazide as 2·5 mg 
once daily. 
-Primary endpoint events occurred in 
363 patients in the captopril group (11·1 per 
1000 patient years) and 335 in the conventional-
treatment group 
( 1 0 · 2 per 1000 patient-years; relative risk 
1·05 [95% CI 
0·90–1·22], p=0·52). -Cardiovascular mortality 
was lower with captopril than with conventional 
treatment (76 v s 9 5 
events; relative risk 0·77 [0·57–1·04], p=0·092), 
the rate of 
fatal and non-fatal myocardial infarction was 
similar (162 v s 
161), but fatal and non-fatal stroke was more 
common with 
captopril (189 vs 148; 1·25 [1·01–1·55]. 
p=0·044). 
-Captopril and conventional 
treatment did not 
differ in efficacy in preventing 
cardiovascular morbidity and 
mortality. -The difference in 
stroke risk is probably due to the 
lower levels of blood pressure 
obtained initially in previously 
treated patients randomised to 
conventional therapy. 
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Outcomes in hypertensive 
patients at high 
cardiovascular risk treated 
with regimens based on 
valsartan or amlodipine: 2004 
 
to test the hypothesis that for the 
same blood-pressure control, 
valsartan would reduce cardiac 
morbidity and mortality more 
than amlodipine in hypertensive 
patients at high cardiovascular 
risk. 
 
-randomised, double-blind, 
parallel-group comparison 
study -15 245 patients, aged 
50 years or older with treated 
or untreated hypertension 
and high risk of cardiac 
events participated in therapy 
based on valsartan or 
amlodipine. 
-Duration of treatment was 
event-driven and the trial 
lasted until at least 1450 
patients had reached a 
primary endpoint, Patients 
from 31 countries were 
followed up for a mean of 
4—2 years. 
 
cardiac mortality and morbidity 
 
intervention 
 
valsartan and amlodipine 
The primary composite endpoint occurred in 810 
patients in the valsartan group (10·6%, 25·5 per 
1000 patient-years) and 789 in the amlodipine 
group (10·4%, 24·7 per 1000 patient-years; 
hazard ratio 1·04, 95% CI 0·94—1·15, p=0·49). 
The main outcome of cardiac 
disease did not differ between the 
treatment groups. 
Effects of candesartan on 
cardiovascular outcomes in 
Japanese hypertensive 
patients. 2005 
To determine whether ARBs are 
effective for protecting against 
hypertensionrelated organ 
damage in the general Japanese 
population 
single blind, randomized, 
prospective study conducted 
in 1999-2002 and employing 
a total of 2,048 essential 
hypertensive subjects (sitting 
blood pressure 140-180/90 
110 mmHg) aged 35-79 
years. 
Subjects were randomly assigned to receive 
the ARB candesartan, 2 to 12 mg daily, or 
conventional antihypertensive drugs other 
than angiotensin converting enzyme inhibitors 
or ARBs. 
 
The primary outcome was assessed by 
hospitalization due to stroke, myocardial 
infarction, and congestive heart failure. 
There was a 39% reduction in hospitalization for 
stroke (5.8 vs. 9.4 cases: relative risk [RR]: 0.61; 
95% confidence interval [CI]: 0.41-0.84; 
p<0.05) and a 57% reduction in hospitalization 
for myocardial infarction (RR: 0.44; CI: 0.21-
0.84; p<0.05) with the candesartan-based 
treatment compared with the conventional 
treatment. In spite of a significant difference in 
the total incidence of both stroke and myocardal 
infarction, there was no significant reduction in 
the incidence of congestive heart failure (15% 
reduction: 4.3 vs. 5.0; RR: 0.85; CI: 0.57-1.26). 
-Further analysis in stratifying the subjects with 
or without a past history of cardiovascular 
diseases including stroke and myocardal 
infarction revealed that candesartan reduced the 
incidence of stroke (61% reduction; RR: 0.39; 
CI: 0.15-0.43; p<0.01) and congestive heart 
failure (49% reduction; RR: 0.51; CI: 0.23-0.92; 
p<0.05) but not myocardial infarction (RR: 0.74; 
CI: 0.36-1.48; p=0.1) in hypertensive patients 
with a past history. However, conventional 
treatment was superior to candesartan-based 
treatment in reducing the incidence of stroke in 
the patients without a past history of 
cardiovascular diseases (66% reduction; RR: 
0.34; CI: 0.16-0.69; p<0.05). 
ARB-based antihypertensive 
treatment was superior to the 
conventional treatment for 
reducing the risk of stroke and 
myocardial infarction in Japanese 
hypertensive patients, especially 
in the patients with a past history 
of cardiovascular diseases. 
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Cardiovascular events in 
elderly patients with isolated 
systolic hypertension. 
To evaluate cardiovascular 
mortality and morbidity in 
elderly hypertensives comparing 
treatment with conventional 
drugs (diuretics, beta-blockers) 
with that of newer ones 
(ACEinhibitors, calcium 
antagonists]. 
Randomized trial 
6614 elderly patients with 
hypertension (mean age 76.0 
years, range 70-84 years at 
baseline) were included. 
Among these 2280 patients 
had isolated systolic 
hypertention 
patients were randomized to one of three 
treatment groups: "conventional" 
antihypertensive therapy with beta-blockers or 
diuretics (atenolol 50 mg, metoprolol 100 mg, 
pindolol 5 mg, or fixed-ratio 
hydrochlorothiazide 25 mg plus amiloride 2.5 
mg daily); ACE inhibitors (enalapril 10 mg or 
lisinopril 10 mg daily); or calcium antagonists 
(felodipine 2.5 mg or isradipine 2.5 mg daily). 
-Analysis was by intention to treat. 
the primary endpoints of the study were 
cardiovascular mortality, fatal and non-fatal 
stroke 
All stroke events, i.e. fatal and non-fatal stroke 
together, were significantly reduced by 25% in 
the newer-drugs group compared with the 
conventional group (95% CI 0.58-0.97; 
p=0.027). This difference was attributable to 
reduction of non-fatal stroke while fatal stroke 
events did not differ between groups. New cases 
of atrial fibrillation were significantly increased 
by 43% (95% CI 1.02-1.99; p=0.037) on 
"newer" drugs compared with "conventional" 
therapy, mainly attributable to the calcium 
antagonists. There were no significant 
differences between the three treatment groups 
with respect to the risks of myocardial 
infarction, sudden death or congestive heart 
failure. 
(ACE inhibitors/calcium 
antagonists) was significantly 
better (25%) than "conventional" 
(diuretics/beta-blockers) in 
preventing all stroke in elderly 
patients with isolated systolic 
hypertension. 
Randomised trial of old and 
new antihypertensive drugs in 
elderly patients: 
cardiovascular mortality and 
morbidity the Swedish Trial 
in Old Patients with 
Hypertension 
1999 
 
 
To compare the effects of 
conventional (diuretics and beta 
blokers) and newer 
antihypertensive (ACEI)drugs 
on cardiovascular mortality and 
morbidity in elderly patients. 
 
prospective, randomised trial 
in 6614 patients aged 70-84 
years with hypertension 
(blood pressure > or = 180 
mm Hg systolic, > or = 105 
mm Hg diastolic, or both). 
Patients were randomly assigned to 
conventional antihypertensive drugs (atenolol 
50 mg, metoprolol 100 mg, pindolol 5 mg, or 
hydrochlorothiazide 25 mg plus amiloride 2.5 
mg daily) or newer drugs (enalapril 10 mg or 
lisinopril 10 mg, or felodipine 2.5 mg or 
isradipine 2-5 mg daily). 
-Out comes were fatal stroke, fatal myocardial 
infarction, and other fatal cardiovascular 
disease. 
-Analysis was by intention to treat. 
The primary combined endpoint of fatal stroke, 
fatal myocardial infarction, and other fatal 
cardiovascular disease occurred in 221 of 2213 
patients in the conventional drugs group (19.8 
events per 1000 patient-years) and in 438 of 
4401 in the newer drugs group (19.8 per 1000; 
relative risk 0.99 [95% CI 0.84-1.16], p=0.89). 
The combined endpoint of fatal and non-fatal 
stroke, fatal and non-fatal myocardial infarction, 
and other cardiovascular mortality occurred in 
460 patients taking conventional drugs and in 
887 taking newer drugs (0.96 [0.86-1.08], 
p=0.49). 
Old and new antihypertensive 
drugs were similar in prevention 
of cardiovascular mortality or 
major events. Decrease in blood 
pressure was of major importance 
for the prevention of 
cardiovascular events. 
 
Comparison Between 
Valsartan and Amlodipine 
Regarding 
Cardiovascular Morbidity and 
Mortality in Hypertensive 
Patients With Glucose 
Intolerance 
To compare 
the efficacies on cardiovascular 
outcomes between ARB and 
CCB in hypertensive patients 
with glucose intolerance. 
- prospective, open-labeled, 
randomized, controlled trial 
-A total of 1150 patients 
(women: 34%; mean age: 63 
years; diabetes mellitus: 
82%) 
The median follow-up period 
was 3.2 years. 
Primary outcome was a composite of acute 
myocardial infarction, stroke, coronary 
revascularization, admission attributed to 
heart failure, or sudden 
cardiac death. 
primary outcome had occurred in 54 
patients in the valsartan group and 56 in the 
amlodipine group (hazard ratio: 0.97 [95% CI: 
0.66 –1.40]; P_0.85). 
Patients in the valsartan group had a 
significantly lower incidence of heart failure 
than in the amlodipine group (hazard ratio: 0.20 
[95% CI: 0.06–0.69]; P_0.01). Other 
components and all-cause mortality were not 
significantly different between the 2 groups. 
Composite cardiovascular 
outcomes were comparable 
between the valsartan- and 
amlodipinebased 
Treatment -Admission because of 
heart failure was significantly less 
in the valsartan group 
Comparison of 
antihypertensive treatments in 
preventing cardiovascular 
events in elderly diabetic 
patients: results from the 
Swedish Trial in Old Patients 
with Hypertension-2. STOP 
Hypertension-2 Study Group. 
2000 
To determine the effect of 
different antihypertensive drugs 
on the frequency of myocardial 
infarction in elderly diabetic 
patients 
prospective, randomized, 
open trial with blinded 
endpoint evaluation 6614 
elderly patients aged 70-84 
years; 719 of them had 
diabetes mellitus at the start 
of the study (mean age 75.8 
years). 
Patients were randomly assigned to one of the 
three treatment strategies: conventional 
antihypertensive drugs (diuretics or beta-
blockers), calcium antagonists, or angiotensin 
converting enzyme (ACE) inhibitors. primary 
endpoints were. 
Reduction in blood pressure was similar in the 
three treatment groups of diabetics. The 
prevention of cardiovascular mortality was also 
similar; the frequency of this primary endpoint 
did not differ significantly between the three 
groups. There were, however, significantly 
fewer (P = 0.025) myocardial infarctions during 
ACE inhibitor treatment (n = 17) than during 
calcium antagonist treatment (n = 32; relative 
risk 0.51, 95% confidence interval 0.28-0.92); 
but a (non-significant) tendency to more strokes 
during ACE inhibitor treatment (n = 34 
compared with n = 29; relative risk 1.16, 95% 
confidence interval 0.71-1.91). 
Treatment of hypertensive 
diabetic patients with 
conventional antihypertensive 
drugs (diuretics, beta-blockers, or 
both) seemed to be as effective as 
treatment with newer drugs such 
as calcium antagonists or ACE 
inhibitors 
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4. Conclusion 
As compared to placebo every antihypertensive drug reduces 
the risk of total major cardiovascular events. CCBs and ACEIs 
are better than diuretics and beta blockers in preventing stroke. 
CCB are far more superior in reducing the risk of stroke than 
ACEIs. For essential hypertensive patients the ability of the 
drug to prevent stroke depends on the previous cardiovascular 
disease history. 
The risk of myocardial infraction can be better reduced by 
using ARBs and ACEIs. But these two drug classes are found 
to be equally effective in patients with isolated systolic 
hypertension. Diuretics should be preferred than beta blockers 
in order to reduce the risk of myocardial infraction. ACEIs and 
diuretics are superior to CCB, beta blockers and alfa blockers 
in preventing heart failure in hypertensive patients. All of the 
antihypertensive drugs did not have a significant difference in 
prevention of cardiovascular mortality. ACEI, CCB and ARB 
drugs are equally effective in their ability to reduce 
cardiovascular morbidity. Thiazide-type diuretics are superior 
than CCB and ACEI in preventing cardiovascular morbidity.  
In hypertensive patients who had also diabetics ACEI and 
CCB have equal effectiveness with diuretics and beta blockers 
to reduce cardiovascular mortality. The risk of myocardial 
infraction in this type of patients is better reduced by using 
ACEIs than diuretics, beta blockers and CCBs. CCB are better 
than ACEIs to reduce the risk of stroke. Losartan is better for 
diabetic hypertensive patients to prevent cardiovascular 
mortality and morbidity than atenolol. Valsartan is better than 
amlodipine to prevent heart failure risk in this type of patients. 
 
5. Abbreviations  
ACEI Angiotensin Converting Enzyme Inhibitor 
ARB Angiostension Receptor Blocker 
BB Beta Blocker 
CCB Calcium Channel Blocker 
CHD Coronary Heart Disease 
CV Cardio-Vascular 
RCT Randomized Controlled Trial  
SBP Systolic Blood Pressure 
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